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ABSTRACT 
Background 
Novel antimicrobial treatments are urgently needed. Previous work has shown that the mucus of the 
brown garden snail (Cornu aspersum) has antimicrobial properties, in particular against type culture 
collection strains of Pseudomonas aeruginosa.  We hypothesised that it would also be effective 
against clinical isolates of the bacterium and that investigation of fractions of the mucus would 
identify one or more proteins with anti-pseudomonal properties, which could be further 
characterised.  
Materials and methods: Mucus was extracted from snails collected from the wild. Antimicrobial 
activity against laboratory and clinical isolates of Ps.  aeruginosa was determined in disc diffusion 
assays. Mucus was purified using size exclusion chromatography and fractions containing anti-
pseudomonal activity identified.  Mass spectroscopy and high performance liquid chromatography 
analysis of these fractions yielded partial peptide sequences. These were used to interrogate an RNA 
transcriptome generated from whole snails. 
Results: Mucus from C. aspersum inhibited growth of type collection strains and clinical isolates of Ps. 
aeruginosa. Four novel C. aspersum proteins were identified; at least three are likely to have 
antimicrobial properties. The most interesting is a 37.4 kDa protein whilst smaller proteins, one 17.5 
kDa and one 18.6 kDa also appear to have activity against Ps. aeruginosa. 
Conclusions: The study has identified novel proteins with antimicrobial properties which could be 
used to develop treatments for use in human medicine. 
Key words: antimicrobial; transcriptome; lectin; mucus; Cornu aspersum, Pseudomonas aeruginosa, 
transcriptome 
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Introduction   
Antimicrobial resistance is a major public health problem [1] and scientists and clinicians 
need to devise protocols that encourage more efficient and sparing use of antimicrobial 
agents [2, 3] in order to limit this. Multidrug resistant strains of many important pathogens, 
including Pseudomonas aeruginosa have emerged [4]. Thus, there is a requirement to 
develop new antimicrobial agents. One approach is to investigate mechanisms of resistance 
and thereby design drugs that can overcome them [5]. Another is to explore the reliability of 
accounts of the effectiveness of natural remedies.  This has yielded some significant 
outcomes including the development of artemisinin to treat chloroquine–resistant strains of 
the malaria parasite Plasmodium spp. [6] and tea tree oil for skin infections [7].   
Ps .aeruginosa is an opportunistic pathogen in humans; it is associated with a range of 
clinical presentations, including lower respiratory tract infections, septicaemia, wound 
infections and ear infections [8]. Nosocomial acquisition is a risk, especially in 
immunocompromised patients and those with severe burns [9]. Patients with cystic fibrosis 
are especially susceptible to respiratory infections with Ps. aeruginosa. Infection can be 
intractable, since the bacteria form biofilms within the lungs which antibiotics cannot fully 
penetrate [10]. Multidrug resistant and extreme multidrug resistant strains of Ps. 
aeruginosa are of increasing concern [8, 10]. The bacterium is ubiquitous in the 
environment and pseudomonal infections are found in vertebrates, invertebrates and plants 
[11, 12]. Therefore, the strategies different organisms employ for defence against Ps. 
aeruginosa might be a source of naturally occurring antimicrobial agents, which could be 
used in human medicine.    
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The common brown garden snail, Cornu aspersum (Helix aspersa) has been valued for its 
healing properties since ancient times [13]. Snail-based remedies have been advocated for 
the treatment gastrointestinal and respiratory conditions, infections characterised by rashes 
(including measles and smallpox), hernias and skin lesions [13]. Terrestrial molluscs secrete 
mucus, which is a viscous and biochemically complex substance. It facilitates locomotion, 
helps reduce water loss, acts as a defence against predators and its components enable 
communication between snails of the same species [14].  Among the constituents of snail 
mucus are glycoproteins, some of which are lectins with agglutination properties [15].  
Cosmetic preparations containing extracts of C. aspersum mucus are currently widely 
marketed for the reduction of wrinkles and scarring [16, 17]. However, mucus extracts also 
promote healing of burn wounds [18] and preliminary work indicates that they have anti-
tumour properties and might have promise for treating melanogenesis [19]. To date, there 
have been few studies on the antimicrobial properties of the mucus of terrestrial molluscs 
[20] and most workers have focussed on the African Giant Land snail, Achatina fulica. Its 
mucus contains a 160 kDa glycoprotein ‘achacin’, which displays fairly broad-spectrum 
antimicrobial properties [21, 22, 23, 24] and a 9 kDa antimicrobial peptide [25].  C. aspersum 
mucus also has antimicrobial activity, attributable to one or more proteins between 30 and 
100 kDa in size [26, 27]. There are two candidate proteins in this range – one approximately 
50 kDa [26, 27] and the other estimated as between 30 and 40 kDa [26] or 41 kDa [27].  
In previous studies, preparations of C. aspersum mucus exhibited very clear activity against 
several laboratory-adapted culture collection strains of Ps. aeruginosa [26]. To investigate 
whether C. aspersum contains antimicrobial agents that would be clinically useful, tests 
against bacteria isolated from patients are required. Testing of Ps. aeruginosa strains 
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obtained from patients with cystic fibrosis would be the logical place to start this work. In 
addition, development of any such product requires identification and characterisation of 
the protein (s) responsible for the observed effects.   
Therefore, the hypotheses for this  present study were 
1. C. aspersum mucus contains one or more proteins that have antimicrobial activity 
against Ps. aeruginosa. 
2. The protein(s) is/ are distinct from the antimicrobial peptide achacin previously 
described by other workers 
 
  
 
 
Materials and methods  
Snail care, mucus collection and preparation  
Twenty Cornu aspersum snails were collected from the wild in East Sussex, UK . They were 
placed in clear plastic tanks, part-filled with moist coconut husk substrate. These were kept 
in a room with ambient light and average temperature of 20 °C. The snails were fed 
cucumber, butternut squash, green peppers, lettuce, and carrots and a provided with a 
source of calcium. 
Mucus was collected by stimulating the snails with a cotton swab moistened in phosphate 
buffered saline (PBS) as described previously [26]. Mucus was harvested using a 5mL plastic 
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Pasteur pipette and, after settling at room temperature for 1-2 hours, placed into a 20mL 
sterile plastic bijou bottle and diluted approximately 1:2 with PBS. The preparation method 
was modified to include an additional step of placing  2-4  8mm glass beads into the bijou 
before shaking overnight (18-20 hours) at 4 °C. The shaken mucus was centrifuged at 4000 
rpm for 20 minutes to sediment large debris. The resulting supernatant was passed through 
a 0.45 micron filter after which its protein content was determined using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, East Grinstead, West Sussex, UK) and found to be 
between 4.0 and 8.0mg/ mL  (n=4). 
As required, size separation was carried out in Vivaspin 500 columns (Sartorius Stedim Lab 
Ltd, Stonehouse, Gloucestershire, UK) at 1,000 kDa , 100 kDa, 30 kDa. The filtrate from the 
1,000 kDa column was used to eliminate larger proteins. The 100 kDa and 30 kDa separation 
columns were used to concentrate the mucus fraction containing proteins between those 
two sizes, since previous work [26] had identified the active ingredient in C. aspersum to be 
in that size band.  
 
Antimicrobial testing   
Mucus  was tested for anti-microbial activity against Ps. aeruginosa NCIMB 10548,   Ps. 
aeruginosa NCTC 10662 and  five well characterised clinical isolates of Ps. aeruginosa . 
These were isolates 2, 9, 10, 34 and 43 from the panel compiled by Soyza et al.  [28], which 
all originated from patients with cystic fibrosis.    
Disc diffusion assays were undertaken as previously described [26] using overnight Tryptone 
Soy Broth (Oxoid, Basingstoke, Hampshire, UK) cultures , diluted in PBS to between 106 and 
107  colony forming units (cfu) per mL (verified by viable count). Aliquots of 100 L were 
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pipetted onto Isosensitest agar (ISA; Oxoid) plates and left to dry for 15 minutes. Then 
between three and six 5 mm sterile assay discs were placed on the plates and 50 L of 
prepared mucus added to each disc. Every plate set up included a PBS control disc. Plates 
were left to dry for a further 40-60 minutes before incubation overnight (18-20 hours), 
aerobically at 37 °C. Zones of inhibition were recorded in mm. A minimum of three 
replicates was tested against a particular strain of bacterium, but in most cases it was more 
than six.  
 
Size Exclusion Chromatography (SEC) 
Prepared C. aspersum mucus was loaded on to a Superdex 75 16/60 column (GE Healthcare 
Life Sciences, Little Chalfont, Buckinghamshire, UK), previously equilibrated with PBS. The 
column was run at 1 mL/min and fractions of 1.5 mL were collected. These fractions were 
submitted to SDS-PAGE and those showing the same protein pattern were pooled, 
concentrated using a 5 kDa cut -off Millipore spin filter and analysed by SDS-PAGE. Two 
proteins which appeared to be present in high concentrations were cut out from the gel and 
sent for analysis by Mass Spectroscopy.  
This experiment was repeated using a Superdex 75 26/60 column (GE Healthcare Life 
Scientific), with the column run at 2 ml/min and fractions of 2 ml. The elution profile, 
monitored at 280nm showed several peaks. Eluted fractions were bulked into pools 
(labelled 1-6), based on protein pattern. Five of the resulting pools (2 to 6) were tested in 
duplicate against Ps. aeruginosa NCIMB 10548 in the disc diffusion assay described above 
and they were also examined by SDS-PAGE. One of the proteins observed was excised from 
the gel and analysed further by HPLC – chromatogram sequencing.  
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Mass Spectrometry 
Proteins selected for further analysis were separated using SDS-PAGE taking account of 
precautions to minimise keratin contamination. The resulting gel was sent to Dr Steve 
Lynham and Dr Malcolm Ward from the Centre of Excellence for Mass Spectrometry, King’s 
College London. Two proteins from the SDS-PAGE were selected for MS analysis, one of 
approximately 50 kDa and the other estimated to be between 17 and 18 kDa in size. 
Selected proteins were excised from the gel and de-stained then reduced (with 
dithiothreitol {DTT}), treated with iodoacetamide (to alkylate any free cysteine residues) and 
digested overnight with trypsin.  The resulting peptide fragments were washed and then 
lyophilised after which they were re-suspended in 50mM ammonium bicarbonate. The 
suspensions were then subjected to reverse phase chromatography in an EASY NanoLC 
(Thermo Scientific) Ultra HPLC analyser and the eluted peptides ionised by electrospray and 
fragmented in an Orbitrap Velos Pro using collision-induced dissociation. The 20 ions that 
registered most strongly were analysed in the Proteome Discover V1.4 software and 
compared to peptide sequences in the Uniprot database. The data were also analysed with 
the PEAKS mass spectrometry software. Resulting peptides were sent to Dr Chris Taron from 
New England Biolabs, MA for comparison with  sequences in a Helix pomatia database.  
 
HPLC-chromatogram sequencing  
Prepared mucus was concentrated by passing it through 1MDa and 100 kDa Vivaspin 500 
columns (Sartorius) and running out in an SDS-PAGE gel. The fraction of interest (30-40 kDa) 
was cut and sent to The Proteome Factory AG, Berlin, Germany, where sequencing analysis 
was undertaken by Ms Julia Schendel. Using HPLC–chromatogram analysis a series of 
peptides was obtained after digestion with trypsin, chymotrypsin, elastase and LysC.  
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RNA transcriptome sequencing 
Individual C. aspersum snails were stimulated to produce mucus as described above and 
then snap frozen in liquid nitrogen. After freezing, the shell was broken off and the body 
ground to a paste in a pestle and mortar; the pestle and mortar were kept cold throughout 
this process. Total RNA was extracted using the E.Z.N.A.(r) Mollusc RNA Kit (Omega BIO-TEK, 
Norcross, USA.),  following the manufacturer’s instructions for the long protocol. Total RNA 
was quantified for purity and integrity by UV-Vis spectroscopy (NanoDrop, Thermoscientific, 
UK). Samples were then stored at -80oC before transport to The University of Liverpool, 
Centre for Genomic Research. RNA was further purified using an RNA Clean & Concentrator 
kit (Zymo Research, USA) and total RNA quantified using a 2100 Agilent Bioanalyzer (RNA 
Nanochip, Agilent Technologies, Germany).    
The sample was treated with a Teloprime full length cDNA amplification kit (Lexogen GmbH) 
following the manufacturer’s protocol. The product was checked for concentration and 
profile using a bioanalyser high sensitivity chip.  
The ends of the sample were damage and end repaired using the Template preparation kit 
(Pacific Biosciences). After cleaning with Ampure XP beads (Beckman Coulter), the sample 
was ligated to PB adapter overnight at 25°C. The SMRTbell library was treated with 
exonuclease to remove non circular DNA. The SMRTbell library was cleaned and this was 
used to load sequel cells using diffusion loading at 6pM on plate concentration and a 2 hour 
pre extension. 
The resulting PacBio READS were analysed at the   University of Liverpool, Centre for 
Genomic Research using the ISO-seq pipeline (SMRT link software 5.0.1.9585) with the 
default parameter settings. The transcriptome was annotated using TransDecoder (version 
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3.0.1) for each strand and protein sequences were annotated using BLASTp (National Center 
for Biotechnology Information [NCBI], Bethesda, MD;http://www.ncbi.nlm.nih.gov/BLAST/). 
Protein sequences with a blast e-val below 0.01 were selected as best match.  
The transcriptome was probed using the peptide sequences obtained from Mass 
Spectroscopy and HPLC using BLASTn. Matches to transcripts were further analysed using 
the EXPASY translate tool (https://web.expasy.org/translate/) to search for open reading 
frames. Proteins found to match to the relevant peptides were analysed using BLASTp.  
 
 
Results 
Antimicrobial spectrum of activity in C. aspersum mucus 
Zones of inhibition were observed in all cases when the mucus was tested against the 
laboratory strains and clinical isolates of Ps. aeruginosa. Figure 1 is an example of an anti-
microbial disc diffusion assay plate where mucus was tested against Ps. aeruginosa NCIMB 
10548.  It shows a very narrow zone of clearing (<0.1mm) around the PBS control and 
obvious zones of inhibition around the three control discs. The mean zones of inhibition 
recorded for the culture collection and clinical isolates of Ps. aeruginosa were all between 9 
and 13mm.    
 
Size exclusion chromatography of C. aspersum mucus proteins 
During the first Superdex column run, two peaks were eluted. Although one of these peaks 
appeared to represent three distinct protein fractions, they all showed similar protein 
patterns on SDS-PAGE. One of these fractions (A) is shown in Figure 2a, along with the 
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proteins from the second peak (B). There were strongly staining bands at approximately 50 
kDa and 17 kDa and these two bands were sent for Mass Spectroscopy.  
 
Figure 2b shows the trace obtained from the second SEC procedure; the peaks are labelled 1 
to 6, where 1 contains the protein aggregates. Figure 2c is the SDS-PAGE gel carried out on 
the fractions on the day of the SEC experiments, indicating the proteins detected in each 
fraction. Table 1 shows the estimated sizes of the proteins detected in each fraction and 
which ones were found to have antibacterial activity.  
 
Peptides identified in C. aspersum mucus from mass spectrometry analysis and HPLC-
chromatographic analysis.  
From the first SEC experiment the ~17 kDda and the ~50 kDa proteins (indicated in Figure 
2a) were selected for Mass Spectrometry analysis. Table 2 shows the putative peptides 
obtained after deduction in comparison with a H. pomatia database.  After the antimicrobial 
analysis of the fractions from the second SEC (Table 2), the protein of approximately 39 kDa 
was sent for the HPLC-chromatographic analysis; the peptides obtained from this are also 
shown in Table 2. Using these peptides to probe the transcriptome database, four proteins 
were identified, as indicated in Table 2.   
 
Transcriptome sequencing and assembly 
Using the peptide sequences (Table 2) to probe the proteins identified in the RNA 
transcriptome revealed that peptide 1 aligned to a single match in the transcriptome. This 
sequence had 4 open reading frames, the longest of which is a protein sequence of 159 
amino acids (17.5 kDa) (protein 1), (Figure 3). Protein 1 contains a conserved region of the 
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complement Cq1 superfamily. Protein 1 has been submitted to the NCBI GenBank and 
allocated the accession number MK393387. 
A combination of peptides 3, 5 and 6 matched to a 583 amino acid protein (64 kDa) that was 
identified as protein 2 (Figure 3).   
Peptide 11 matched to a 169 amino acid protein (18.6 kDa) (Figure 3) that was identified as 
protein 3. Amino acids 1- 155 map to a conserved region in the fibrinogen related domain 
(FReD) superfamily. Protein 3 has been submitted to the NCBI GenBank and allocated the 
accession number MK393388. 
 
A combination of peptides 12, 13, 14, 15, 16, 17 and 18 matched to a protein of 340 amino 
acids in length (37.4 kDa), labelled protein 4 (Figure 3). This sequence appeared in three 
separate places in the transcriptome. Two of these sequences have been submitted to the 
NBCI GenBank and allocated the accession numbers MK393385 and MK393386. Amino acids 
150 to 340 map to a conserved region from the von Willebrand Factor A superfamily.  
 
Discussion  
This study has confirmed the findings of Pitt et al. [26] and Bortolotti et al. [27] that C. 
aspersum mucus contains one or more proteins with anti-microbial activity against Ps. 
aeruginosa. The results for the antimicrobial plate assay were essentially qualitative, since 
the concentration of the active ingredient(s) within the mucus was not known. 
Nevertheless, clear and reproducible zones of inhibition were obtained not only with the 
type culture collection strains, but with all five clinical isolates which came from patients 
with cystic fibrosis.      
13 
 
This is an important finding as it indicates that further characterisation of the active 
ingredient(s) is justified. Previous work on C. aspersum mucus identified two possible 
proteins in the size range of between 30 kDa and 100 kDa on SDS-PAGE with anti-microbial 
activity against Ps. aeruginosa [26, 27] and this was confirmed by repeated plate assays (S. 
Pitt, unpublished data) and Minimum Inhibitory Concentration experiments (J. Hawthorne, 
unpublished data). One of the proteins is between 50 and 60 kDa and the other between 30 
and 40 kDa. Analysis by SDS-PAGE of the fractions of mucus obtained by the SEC procedure 
revealed proteins that corresponded with these sizes (Figures 2a and 2c). In addition, the 
SDS-PAGE of the unfractionated mucus showed clear bands in the 10-20 kDa size regions 
(Figures 2a and 2b). Some or all of these are likely to be lectins, which are common 
components of gastropod mucus. There are various classes of lectins and some of them 
function in the invertebrate immune response [29, 30]. Lectins also play a role in mollusc 
mucus function, including binding /attaching to substrates and contributing to viscosity. 
They have also been found to have unexpected properties with respect to binding 
mammalian cells. For example, C. aspersum mucus extracts promote wound healing by 
stimulating the proliferation and migration of mammalian fibroblasts [31]. Similarly, the 
ability of the H. pomatia agglutinin (HPA) to attach to mammalian cells expressing the N-
acetylgalactosamine surface protein, which is a marker of malignancy. A 12 kDa lectin with 
similar properties is present within C. aspersum mucus. It binds to very specific mammalian 
cell surface markers and has been extensively characterised with a view to using it in 
diagnostic assays for cancers and other conditions [15].  
Previous size separation experiments with C. aspersum mucus found that component 
proteins less than 30kDa in size did not appear to express antimicrobial activity [26]. 
Therefore, the identification of a 17.5 kDa protein (‘protein 1’) with possible anti-microbial 
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activity (Table 1, Table 2,  Figure 3) which appears to be a sialic acid binding lectin was an 
unexpected finding (Figure 6a). Some lectins have pathogen recognition receptor (PRR) 
properties [30] and this could contribute to the anti-microbial activity. Gastropod lectins 
have been known about for some time but to date none have been exploited for anti-
microbial treatments. Another unexpected finding was the 18.6 kDa protein (‘protein 3’) 
within the 30-40 kDa  mucus fraction ( Table 2, Figure 3, Figure 4c). The sequence suggests 
that it has a region consistent with the fibrinogen related domain (FreD). While fibrinogens 
are well known and characterised in mammals for their role in coagulation, they are also 
part of the invertebrate defence mechanism. FReDs work as part of the internal immune 
system and they have agglutination and lectin-like binding properties [32]. However, some 
FReDs with PRR and bacteriolytic properties – at least in vitro – are present in animals 
including shrimp [33] and amphioxus [34]. Although the presence of the 18.6 kDa protein in 
the anti-pseudomonal fraction of the mucus noted here could be co-incidental, this might 
equally play an important function in the observed anti-bacterial effect.  
The initial SEC experiments suggested that the protein of around 50 kDa was present in 
large concentrations.  It was therefore selected for sequencing by mass spectroscopy. The 
second SEC and testing of the fractions against Ps. aeruginosa indicated that this protein 
probably lacks antimicrobial activity. As Table 1 shows, the 50 kDa protein was present in 
fractions 3, 4 and 5, although only the first and last of these showed antibacterial activity. 
Probing of the RNA transcriptome with the resulting peptides revealed a slightly larger 
protein of 64 kDa, ‘protein 2’ (Table 2, Figure 3). It remains unclear whether this is the 
protein identified as 50 kDa in the first SEC experiment. Protein 2 seems likely to be an 
extracellular matrix protein. 
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Strong anti-pseudomonal activity was observed with fraction 6 (Table 1) which contained 
the protein between 30 and 40 kDa. The work following this up has identified a 37.4 kDa 
protein, ‘protein 4’ (Table 2, Figure 3). It was found in three separate places in the 
transcriptome, which suggests it is important for the snail. Reports of proteins in this mass 
range within invertebrates are limited, but they function as part of the mammalian innate 
immune response and some have anti-microbial properties. For example, cathelicidin LL-37 
has activity against E. coli, Candida albicans and Staph. aureus [35]. Another protein, CAP-37 
[36] appears to target Gram negative bacteria and has a particularly strong effect on Ps. 
aeruginosa.  The 37.4 kDa protein in C. aspersum mucus shares homology with a predicted 
collagen 6 (IV) protein in another species of snail, Biomphalaria glabrata, and a match to 
conserved domains of the von Willebrand factor A superfamily. Although it is an 
extracellular matrix protein, collagen 6(IV) from mammals has antibacterial properties and 
the significance of the vWFA domains in this effect was recently demonstrated [37].  
Peptides containing the relevant domains are reported to have good activity against 
selected bacteria, including Ps.aeruginosa. This may provide a partial explanation for the 
antimicrobial properties of this novel protein, although BLAST results showed mapping to 
only 55% of the B. glabrata protein. 
The reason for the presence of a substance with targeted anti-pseudomonal activity in C. 
aspersum mucus is not immediately clear. Although Ps.aeruginosa is a common soil 
organism, to which terrestrial snails are continually exposed, there are many other potential 
pathogens in the soil environment. Ps. aeruginosa is a known pathogen of insects, within 
which it employs similar virulence factors to those in mammalian hosts [38]. Pseudomonas 
spp. thrive in the environmental conditions provided by human mucus, especially in the 
lungs of patients with cystic fibrosis [10, 39]. It is therefore possible that snail mucus has 
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similar constituents that can enhance the growth of these bacteria, which necessitates 
specific protection.  Also, a specific immunological interaction between this particular 
mollusc and bacterium has been previously noted. Repeated injection with suspensions 
containing high titres of Ps. aeruginosa have been shown to stimulate a measurable immune 
response in C. aspersum, while preparations containing other microorganisms did not [40]. 
Thus, it appears that the anti-microbial proteins identified here could have a particular 
function in contributing to protection of C. aspersum against Ps. aeruginosa infections. If 
this could be ascertained, it may be possible to exploit it for development of treatment of 
human infections with this bacterium. For example, against Ps. aeruginosa strains 
implicated in serious respiratory infections and infections in deep wounds. Therefore, 
further characterisation of the form and function of all these proteins would be beneficial. 
Production of purified versions of the proteins would make them available in greater 
concentration than has been possible from crude mucus preparations. This would allow 
quantitative antimicrobial assays to be conducted as opposed to the qualitative results 
presented here. Re-investigation of the antimicrobial activity to confirm the specificity 
against Ps. aeruginosa could be conducted.  Detailed observations of the site within the 
bacterial cell and mechanism of action of each of these proteins could be carried out.  
Although four novel proteins have been identified here, the 37.4 kDa protein, to be named 
Aspernin, appears to be the most significant finding and it could be exploited to develop an 
antimicrobial substance for use in human medicine. Because C.  aspersum is farmed 
commercially in several countries, it is already possible to source large numbers of snails at 
low cost. Therefore, unlike many naturally-derived pharmaceutical compounds, sourcing the 
raw material would not be a problem and the antimicrobial components might be separated 
out when the snails are processed for other purposes. This work represents an advance in 
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biomedical science because it has identified a potential novel antimicrobial treatment 
against the clinical important pathogen Ps. aeruginosa. 
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Summary table 
What is known about this subject 
Cornu aspersum mucus has anti-microbial properties 
It is particularly effective against Pseudomonas aeruginosa 
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The antimicrobial effect is attributable to one or more proteins between 30 and 100kDa in 
size 
What this paper adds 
Cornu aspersum mucus is effective against clinical isolates of Ps. aeruginosa 
The mucus contains several proteins with antimicrobial properties 
The most important of these is a 37kDa protein  
 
References 
[1] Holmes AH., Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of 
antimicrobial resistance. Lancet, 2016; 387:176-187. 
[2] WHO World Health Organization. Critically Important Antimicrobials for Human 
Medicine: ranking of antimicrobial agents for risk management of antimicrobial resistance 
due to non-human use. 5th revision, 2016; Geneva: World Health Organization. Retrieved 
from http://apps.who.int/iris/bitstream/10665/255027/1/9789241512220-eng.pdf?ua=1 
[3] Finley RL, Collignon P, Larsson .J. et al. The scourge of antibiotic resistance: the important 
role of the environment. Clin Infect Dis. 2013; 57:704-710. 
[4] Buhl M, Peter S, Willmann M. Prevalence and risk factors associated with colonization 
and infection of extensively drug-resistant Pseudomonas aeruginosa: a systematic review. 
Expert Rev Anti-infect Ther. 2015; 13:1159-1170. 
[5] Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016; 
529: 336-343. 
[6] Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat 
Med. 2011; 17:1217-20. 
19 
 
[7] Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) Oil: A review of 
antimicrobial and other medicinal properties. Clin Microbiol Rev 2006; 19: 50-62. 
[8]  Juan, C, Peña, C, Oliver, A. Host and pathogen biomarkers for severe Pseudomonas 
aeruginosa infections. J Infect Dis 2017; 215(suppl 1): S44-S51. 
[9] Tissot F, Blanc DS, Basset P, et al. New genotyping method discovers sustained 
nosocomial Pseudomonas aeruginosa outbreak in an intensive care burn unit. J Hosp Infect 
2016; 94: 2-7. 
[10] Stefani, S., Campana, S., Cariani, L. et al. Relevance of multidrug-resistant Pseudomonas 
aeruginosa infections in cystic fibrosis. Int J Med Micro 2017; 307: 353-362. 
[11] Ramos J-L, Goldberg JB, Filloux A. Pseudomonas:  Volume 7: New Aspects of 
Pseudomonas Biology. 2016. Berlin, Germany, Springer-Verlag.  
[12] Streeter K, Katouli M. (2016) Pseudomonas aeruginosa: A review of their pathogenesis 
and prevalence in clinical settings and the environment. Infection, Epidemiology and 
Microbiology 2016; 2:25-32. 
[13] Bonnemain B. Helix and drugs: snails for western health care from antiquity to the 
present. Evid Based Complementary Altern Med 2005; 2:25-28 
[14] Greistorfer S, Klepal W, Cyran N, et al. Snail mucus − glandular origin and composition 
in Helix pomatia. Zoology 2017; 122: 126-138. 
[15] Pietrzyk, A, Bujacz, A, Mak P, et al. Structural studies of Helix aspersa agglutinin 
complexed with GalNAc: A lectin that serves as a diagnostic tool. Int J Biol Macromol 2015; 
81:1059-1068. 
[16] Mazzulla S, Anile D, De Sio S, et al. In vivo evaluations of emulsion o/w for a new topical 
anti-aging formulation: short-term and long-term efficacy. JCDSA 2018; 8: 110-125. 
20 
 
[17] Alogna A. New frontiers in snail mucus studies for cosmetic and pharmaceutical 
preparations. Cosmetiscope 2017; 23:1-6. 
[18] Tsoutsos D, Kakagia D, Tamparopoulos K. The efficacy of Helix aspersa Müller extract in 
the healing of partial thickness burns: A novel treatment for open burn management 
protocols. J Dermatolog Treat 2009; 20: 219-222 
[19] Ellijimi C, Hammouda M., Othman H, et al., (2018) Helix aspersa maxima mucus exhibits 
antimelanogenic and antitumoral effects against melanoma cells. Biomed Pharmacother 
2018; 101: 871-880. 
[20] Cilia G, Fratini F. Antimicrobial properties of terrestrial snail and slug mucus. J. 
Complement Integr Med 2018; doi: 10.1515/jcim-2017-0168 
[21] Iguchi SM, Takashi A, Matsumoto JJ. Antibacterial activity of snail mucus mucin. Comp 
Biochem Physiol A Comp Physiol 1982; 72:571-574. 
[22] Kubota Y, WatanabeY, Otsuka H, et al. Purification and characterization of an 
antibacterial factor from snail mucus. Comp Biochem Physiol C Comp Pharamacol 1985; 
82:345-348 
[23] Otsuka-Fuchino H, WatanabeY, Hirakawa C. et al. Bactericidal action of a glycoprotein 
from the body surface of Giant African Land Snail.  Comp Biochem Physiol C Comp 
Pharamacol 1992; 101: 607-613.  
[24] Santana WA, Melo CMD, Cardoso JC, et al. Evaluación de la actividad antimicrobiana y 
la cicatrización potencial de la secreción mucosa de Achatina fulica. Int J Morph 2012; 
30:365-373. 
[25] Zhong J, Wang,W, Yang X, et al. A novel cysteine-rich antimicrobial peptide from the 
mucus of the snail of Achatina fulica. Peptides 2013; 39:1-5. 
21 
 
[26] Pitt SJ, Graham MA, Dedi CG, et al. Antimicrobial properties of mucus from the brown 
garden snail Helix aspersa. Br J Biomed Sci 2015; 72: 174-181. 
[27] Bortolotti D, Trapella C, Bernardi T. et al. Letter to the Editor: Antimicrobial properties 
of mucus from the brown garden snail Helix aspersa. Br J Biomed Sci 2016; 73: 49-50. 
[28] De Soyza A, Hall AJ, Mahenthiralingam E, et al. Developing an international 
Pseudomonas aeruginosa reference panel. Microbiologyopen. 2013; 2:1010-23. 
[29] Gorbushin AM, Borisova EA. Lectin-like molecules in transcriptome of Littorina littorea 
hemocytes. Dev Comp Immunol 2015; 48: 210-220. 
[30] Gerdol M. Immune-related genes in gastropods and bivalves: a comparative overview. 
Invert Surviv J 2017; 14: 95-110. 
[31] Trapella C, Rizzo R, Gallo S, et al.  HelixComplex snail mucus exhibits pro-survival, 
proliferative and pro-migration effects on mammalian fibroblasts. Sci Rep 2018; 8: doi: 
10.1038/s41598-018-35816-3 
[32] Hanington PC, Zhang SM. The primary role of fibrinogen-related proteins in 
invertebrates is defense, not coagulation. J Innate Immun 2011; 3:17-27. 
[33] Wang XW, Wang JX. Diversity and multiple functions of lectins in shrimp immunity. Dev 
Comp Immunol 2013; 39:27-38. 
[34] Fan C, Zhang S, Li L. et al. Fibrinogen-related protein from amphioxus Branchiostoma 
belcheri is a multivalent pattern recognition receptor with a bacteriolytic activity. Mol 
Immunol 2008; 45:3338-3346. 
[35] Burton MF, Steel PG. The chemistry and biology of LL-37. Nat Prod Rep 2009; 26: 1572-
1584. 
22 
 
[36] Kasus‐Jacobi A, Noor‐Mohammadi S, Griffith GL. et al. A multifunctional peptide based 
on the neutrophil immune defense molecule, CAP37, has antibacterial and wound‐healing 
properties. J Leukoc Biol 2015; 9:341-350. 
 [37] Abdillahi, S.M., Maaß, T., Kasetty, G. et al. Collagen VI contains multiple host defense 
peptides with potent in vivo activity. J Immun 2018; 201:1007-1020. 
[38] Jander G, Rahme LG. Ausubel FM. Positive correlation between virulence of 
Pseudomonas aeruginosa mutants in mice and insects. J Bacteriol 2000; 182:3843-3845. 
 [39] Langan KM, Kotsimbos T, Peleg AY. Managing Pseudomonas aeruginosa respiratory 
infections in cystic fibrosis. Curr Opin Infect Dis 2015; 28: 547-556. 
[40] Bayne CJ. Molluscan immunity: induction of elevated immunity in the land snail (Helix) 
by injections of bacteria (Pseudomonas aeruginosa). Dev Comp Immunol 1980; 4:43-54. 
